Compare AstraZeneca plc (AZN) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Cardinal Health Inc — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while Cardinal Health Inc trades at $235.79 (market cap $55.88B). The key difference: AstraZeneca plc is far larger — about 4.4× Cardinal Health Inc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | CAH | |
|---|---|---|
Market Cap | $248.14B | $55.88B |
Sector | Health | Health |
52-Week High | $209.48 | $240.26 |
52-Week Low | $147.06 | $146.04 |
Enterprise Value | $275.41B | $59.91B |
Dividend Yield | 2.01% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.
Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
